Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Return on Equity (2021 - 2023)

Candel Therapeutics' Return on Equity history spans 3 years, with the latest figure at 1.34% for Q3 2023.

  • For Q3 2023, Return on Equity fell 72.0% year-over-year to 1.34%; the TTM value through Sep 2023 reached 1.34%, down 72.0%, while the annual FY2022 figure was 0.63%, 64.0% up from the prior year.
  • Return on Equity for Q3 2023 was 1.34% at Candel Therapeutics, down from 1.02% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.52% in Q1 2021 and bottomed at 2.43% in Q3 2021.
  • The 3-year median for Return on Equity is 0.62% (2022), against an average of 0.67%.
  • The largest YoY upside for Return on Equity was 182bps in 2022 against a maximum downside of -100bps in 2022.
  • A 3-year view of Return on Equity shows it stood at 0.41% in 2021, then tumbled by -71bps to 0.69% in 2022, then crashed by -93bps to 1.34% in 2023.
  • Per Business Quant, the three most recent readings for CADL's Return on Equity are 1.34% (Q3 2023), 1.02% (Q2 2023), and 0.8% (Q1 2023).